Cargando…
RF35 | PSAT269 Double-Blind, Randomized, Placebo-controlled, Multicenter, Phase 2b Study of Batoclimab in Active and Moderate-to-Severe Thyroid Eye Disease
Clinical manifestations of thyroid eye disease (TED) are mainly caused by the binding of immunoglobulin G (IgG) thyrotropin receptors (TSHR) autoantibodies (TSHR-Ab) on orbital fibroblasts. Batoclimab (IMVT-1401) is an anti-neonatal Fc receptor (FcRn) human monoclonal antibody that prevents normal I...
Autores principales: | Kahaly, George, Stan, Marius, Webster, Sara, Liang, Su, Tedeschi, Philip, Janes, Jonathan, Douglas, Raymond |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628267/ http://dx.doi.org/10.1210/jendso/bvac150.1782 |
Ejemplares similares
-
ODP509 Proof-of-concept, Multicenter, Open-Label Phase 2a Study of Batoclimab in Active and Moderate-to-Severe Thyroid Eye Disease
por: Janes, Jonathan, et al.
Publicado: (2022) -
RF35 | PSAT263 Efficacy of Teprotumumab for Thyroid Eye Disease in Hypothyroid Patients
por: Smith, Terry J, et al.
Publicado: (2022) -
RF35 | PSAT257 The Severity of Subacute Thyroiditis Depends on Its Causative Agent
por: Brancatella, Alessandro, et al.
Publicado: (2022) -
RF35 | PSAT298 Subacute Thyroiditis Following SARS-CoV-2 mRNA Vaccine
por: Pandey, Shanta, et al.
Publicado: (2022) -
RF35 | PSAT268 Reversal of Graves’ Disease Associated Facial Volume Expansion and Eyelid Changes Following Teprotumumab Therapy
por: Ugradar, Shoaib, et al.
Publicado: (2022)